TY - JOUR
T1 - The Role of Amyloid-ß in White Matter Damage
T2 - Possible Common Pathogenetic Mechanisms in Neurodegenerative and Demyelinating Diseases
AU - Pietroboni, Anna M.
AU - Colombi, Annalisa
AU - Carandini, Tiziana
AU - Scarpini, Elio
AU - Galimberti, Daniela
AU - Bozzali, Marco
N1 - Funding Information:
This research was supported by the Italian Ministry of Health (Ricerca Corrente to ES). Authors’ disclosures available online (https:// www.j-alz.com/manuscript-disclosures/20-0868r1).
Publisher Copyright:
© 2020 - IOS Press and the authors. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Just as multiple sclerosis (MS) has long been primarily considered a white matter (WM) disease, Alzheimer's disease (AD) has for decades been regarded only as a grey matter disorder. However, convergent evidences have suggested that WM abnormalities are also important components of AD, at the same extent as axonal and neuronal loss is critically involved in MS pathophysiology since early clinical stages. These observations have motivated a more thorough investigation about the possible mechanisms that could link neuroinflammation and neurodegeneration, focusing on amyloid-ß (Aß). Neuroimaging studies have found that patients with AD have widespread WM abnormalities already at the earliest disease stages and prior to the presence of Aß plaques. Moreover, a correlation between cerebrospinal fluid (CSF) Aß levels and WM lesion load was found. On the other hand, recent studies suggest a predictive role for CSF Aß levels in MS, possibly due in the first instance to the reduced capacity for remyelination, consequently to a higher risk of WM damage progression, and ultimately to neuronal loss. We undertook a review of the recent findings concerning the involvement of CSF Aß levels in the MS disease course and of the latest evidence of AD related WM abnormalities, with the aim to discuss the potential causes that may connect WM damage and amyloid pathology.
AB - Just as multiple sclerosis (MS) has long been primarily considered a white matter (WM) disease, Alzheimer's disease (AD) has for decades been regarded only as a grey matter disorder. However, convergent evidences have suggested that WM abnormalities are also important components of AD, at the same extent as axonal and neuronal loss is critically involved in MS pathophysiology since early clinical stages. These observations have motivated a more thorough investigation about the possible mechanisms that could link neuroinflammation and neurodegeneration, focusing on amyloid-ß (Aß). Neuroimaging studies have found that patients with AD have widespread WM abnormalities already at the earliest disease stages and prior to the presence of Aß plaques. Moreover, a correlation between cerebrospinal fluid (CSF) Aß levels and WM lesion load was found. On the other hand, recent studies suggest a predictive role for CSF Aß levels in MS, possibly due in the first instance to the reduced capacity for remyelination, consequently to a higher risk of WM damage progression, and ultimately to neuronal loss. We undertook a review of the recent findings concerning the involvement of CSF Aß levels in the MS disease course and of the latest evidence of AD related WM abnormalities, with the aim to discuss the potential causes that may connect WM damage and amyloid pathology.
KW - Amyloid-ß
KW - inflammation
KW - neurodegeneration
KW - white matter damage
UR - http://www.scopus.com/inward/record.url?scp=85095110780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095110780&partnerID=8YFLogxK
U2 - 10.3233/JAD-200868
DO - 10.3233/JAD-200868
M3 - Review article
C2 - 32925075
AN - SCOPUS:85095110780
VL - 78
SP - 13
EP - 22
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
SN - 1387-2877
IS - 1
ER -